Paul Carter BA, PhD

Paul joined Genentech as a Postdoctoral Fellow in 1986 and left as a Senior Scientist and Head of the Postdoctoral Program in 2000. He then rejoined Genentech in 2010 as a Senior Director and Staff Scientist to lead the Antibody Engineering Department. His most significant contributions to drug development include initiating the antibody humanization program at Genentech. He is a co-inventor of 6 humanized or human antibodies that have reached clinical development, including one humanized antibody that later became a commercial product.
His lab and our collaborators developed ‘knobs-in-holes’ technology that has been widely used by many different organizations for generating bispecific antibodies and other bifunctional molecules. At Genentech, ‘knobs-in-holes’ was included in the design of a one-armed antibody and 5+ bispecific antibodies that have reached clinical trials. His lab also invented common light chain technology used by several different companies for developing 6+ bispecific antibodies that have entered clinical trials including 1 approved product. They also developed technologies for high-level expression of antibody Fab fragments that were subsequently utilized for production of an antibody drug that is now marketed.
He have authored or co-authored 110+scientific publications that together have been cited 17,000+ times. He is a inventor or co-inventor on 45+ granted US patents and 53+ published US patent applications. He have co-organized 15+ international conferences on antibody engineering and antibody therapeutics. He have delivered 110+ conference presentations and invited lectures including 11+ keynote presentations.